Revolutionizing human medicine with molecular glues

DISCOVER MORE

Magnet Biomedicine’s modular platform enables the systematic discovery of true molecular glues towards the treatment of human disease.

Our technology builds upon the discoveries of our Scientific Founders, who provided the seminal observations of molecular glues and have explored them for over 30 years.

shapes image
shapes image
shapes image
shapes image
shapes image
shapes image

THE SCIENCE

Molecular glues are compounds that induce and stabilize interactions between two or more proteins.

Recent advances in the design of bifunctional molecular glues have increased the popularity of E3-ligase-recruiting degraders and have demonstrated the value of recruiting enzymes to therapeutic targets.

However, this subclass represents only a small fraction of the potential of molecular glues. We believe that molecular glues need not recruit enzymatic proteins to impart therapeutic benefit, and that this class of molecular glues represents an untapped reservoir for medicines.

At Magnet Biomedicine, we apply this foundational principle to every aspect of our molecular-glue discovery platform as we evaluate the entire human proteome for our molecular-glue toolbox. Our history in this field dates back to the 1990s, when our Scientific Founders made the seminal discoveries of molecular glues. Tacrolimus (FK506) and sirolimus (rapamycin)—approved by the FDA in 1994 and 1999, respectively—are both molecular glues and demonstrate how simple protein recruitment can result in meaningful drug activity. In fact, these drugs inhibit their targets in a substrate-selective manner by partially blocking the entry portal to the active sites. These transformative therapeutics highlight the flexibility of molecular glues as a drug modality and underscore the rationale for Magnet’s comprehensive approach to molecular-glue medicines.

Our history in this field dates back to the 1990s, when our Scientific Founders made the seminal discoveries of molecular glues.

Tacrolimus (FK506) and sirolimus (rapamycin)—approved by the FDA in 1994 and 1999, respectively—are both molecular glues and provide examples for how simple protein recruitment can result in drug activity. In fact, these drugs inhibit their targets in a substrate-selective manner by partially blocking the entry portal to the active sites.

These transformative examples highlight the flexibility of molecular glues as a modality for drug discovery and underscore Magnet’s comprehensive approach to molecular-glue medicines.

shapes image
shapes image
shapes image

OUR TECHNOLOGY

Building upon recent advances in proteomics, screening, and DNA sequencing, we believe the time is now to execute on these long-standing goals.

By combining state-of-the-art screening technologies and human-biology-driven protein selection, Magnet Biomedicine has developed the means to systematically discover true molecular glues, i.e. those that exhibit cooperative binding.

Our technology can be applied in a target- and indication-agnostic manner to discover a wide range of molecular glues with highly specific activities.

shapes image

THE FOUNDERS

Michael Rosbash

Michael Rosbash, Ph.D.

Stuart Schreiber, Ph.D.

Richa Saxena, Ph.D.

Benjamin F. Cravatt, Ph.D.

OUR INVESTORS

shapes image
shapes image

CAREERS

Magnet Biomedicine is building a world-class team to unleash the scientific breakthroughs and expertise of our Founders.

We are looking for creative, thoughtful, science-first innovators to join our collaborative team. Come help us realize the potential of molecular glues to achieve the broadest possible impact for patients.

Click the job openings to learn more.

VISIT US ON LINKEDIN